Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light
In a rare setback, Merck has suffered a key Phase III failure for Keytruda that could put a crimp in its sales prospects.
The pharma giant reported after the market closed on Tuesday that Keytruda failed the KEYNOTE-240 study for hepatocellular carcinoma, the most common type of liver cancer. The trial missed on both overall survival as well as progression-free survival. That news arrived just 3 months after the FDA offered an accelerated approval on liver cancer based on their earlier mid-stage data for the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
